Skip to main content
Erschienen in: Diabetology International 1/2022

13.08.2021 | Short Communication

A case of α-chain variant hemoglobin (Hb Chad) with falsely high HbA1c levels measured by immunoassay

verfasst von: Kei Yoshino, Yushi Hirota, Wataru Ogawa, Kenji Sugawara, Akira Kawaguchi, Hiroshi Yoshino, Midori Ishibashi, Gen Yoshino, Masafumi Koga

Erschienen in: Diabetology International | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Variant hemoglobin is often detected during the diagnosis and treatment of diabetes mellitus. We here describe a case of α2-chain variant hemoglobin (Hb Chad) that was identified as a result of differences in HbA1cs values determined by different assays. HbA1c measured by immunoassay was thus falsely high, whereas that measured by high-performance liquid chromatography (HPLC) was slightly low. Sequencing analysis revealed a heterozygous GAG (glutamic acid) → AAG (lysine) mutation at amino acid position 23 of the α2-globin gene. This residue is located at the surface of the α-chain in the crystal structure of hemoglobin. The high HbA1c value determined by immunoassay might have been the result of increased antigenicity of the variant hemoglobin, whereas the low value measured by HPLC reflected differential fractionation of the variant relative to the wild-type protein. Hb Chad has been reported in only three cases to date, and HbA1c was measured for the first time. This is the first case where falsely high HbA1c measured by immunoassay due to increased antigenicity in α-chain variant hemoglobin. This case highlights the importance of comparison with other parameters related to plasma glucose such as glycated albumin if an HbA1c abnormality is suspected.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat American Diabetes Association. Glycemic targets: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(suppl 1):S61–70.CrossRef American Diabetes Association. Glycemic targets: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(suppl 1):S61–70.CrossRef
2.
Zurück zum Zitat Koga M. Glycated albumin; clinical usefulness. Clin Chim Acta. 2014;433:96–104.CrossRef Koga M. Glycated albumin; clinical usefulness. Clin Chim Acta. 2014;433:96–104.CrossRef
3.
Zurück zum Zitat Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem. 2001;47:153–63.CrossRef Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem. 2001;47:153–63.CrossRef
4.
Zurück zum Zitat Miyazaki A, Kohzuma T, Kasayama S, Koga M. Classification of variant forms of haemoglobin according to the ratio of glycated haemoglobin to glycated albumin. Ann Clin Biochem. 2012;49:441–4.CrossRef Miyazaki A, Kohzuma T, Kasayama S, Koga M. Classification of variant forms of haemoglobin according to the ratio of glycated haemoglobin to glycated albumin. Ann Clin Biochem. 2012;49:441–4.CrossRef
6.
Zurück zum Zitat Schnedl WJ, Krause R, Halwachs-Baumann G, Trinker M, Lipp RW, Krejs GJ. Evaluation of HbA1c determination methods in patients with hemoglobinopathies. Diabetes Care. 2000;23:339–44.CrossRef Schnedl WJ, Krause R, Halwachs-Baumann G, Trinker M, Lipp RW, Krejs GJ. Evaluation of HbA1c determination methods in patients with hemoglobinopathies. Diabetes Care. 2000;23:339–44.CrossRef
7.
Zurück zum Zitat Thomas LB, Agosti SJ, Man MA, Mastorides SM. Screening for hemoglobinopathies during routine hemoglobin A1c testing using the Tosoh G7 Glycohemoglobin Analyzer. Ann Clin Lab Sci. 2007;37:251–5.PubMed Thomas LB, Agosti SJ, Man MA, Mastorides SM. Screening for hemoglobinopathies during routine hemoglobin A1c testing using the Tosoh G7 Glycohemoglobin Analyzer. Ann Clin Lab Sci. 2007;37:251–5.PubMed
8.
Zurück zum Zitat Boyer SH, Crosby EF, Fuller GF, et al. A survey of hemoglobins in the Republic of Chad and characterization of hemoglobin Chad: alpha-2-23Glu→Lys-beta-2. Am J Hum Genet. 1968;20:570–8.PubMedPubMedCentral Boyer SH, Crosby EF, Fuller GF, et al. A survey of hemoglobins in the Republic of Chad and characterization of hemoglobin Chad: alpha-2-23Glu→Lys-beta-2. Am J Hum Genet. 1968;20:570–8.PubMedPubMedCentral
9.
Zurück zum Zitat Tahara Y, Shima K. Evaluation of error levels in hemoglobin A1c and glycated albumin in type 2 diabetic patients due to inter-individual variability. Diabetes Res Clin Pract. 2010;89:115–20.CrossRef Tahara Y, Shima K. Evaluation of error levels in hemoglobin A1c and glycated albumin in type 2 diabetic patients due to inter-individual variability. Diabetes Res Clin Pract. 2010;89:115–20.CrossRef
10.
Zurück zum Zitat Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ, A1c-Derived Average Glucose Study Group. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31:1473–8.CrossRef Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ, A1c-Derived Average Glucose Study Group. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31:1473–8.CrossRef
11.
Zurück zum Zitat Blackwell RQ, Weng MI, Huang JT. Haemoglobin Chad, alpha23 GLU leads to LYS, in a Chinese family in Taiwan. Trop Geogr Med. 1973;25:393–6.PubMed Blackwell RQ, Weng MI, Huang JT. Haemoglobin Chad, alpha23 GLU leads to LYS, in a Chinese family in Taiwan. Trop Geogr Med. 1973;25:393–6.PubMed
12.
Zurück zum Zitat Harano T, Harano K, Shibata S, et al. Hemoglobin Chad [alpha 23 (B4) Glu replaced by Lys] discovered in a Japanese with questionable polycythemia. Hemoglobin. 1983;7:581–4.CrossRef Harano T, Harano K, Shibata S, et al. Hemoglobin Chad [alpha 23 (B4) Glu replaced by Lys] discovered in a Japanese with questionable polycythemia. Hemoglobin. 1983;7:581–4.CrossRef
13.
Zurück zum Zitat Furuya M, Koga M, Ishibashi M, Toyoda M, Tsujii S. A Case of Variant Hemoglobin HbC in a Non-Diabetic Subject Treated with Anti-Diabetic Drugs Due to Falsely High HbA1c Levels Measured By an Immunoassay. J Japan Diab Soc. 2016;59:463–8. Furuya M, Koga M, Ishibashi M, Toyoda M, Tsujii S. A Case of Variant Hemoglobin HbC in a Non-Diabetic Subject Treated with Anti-Diabetic Drugs Due to Falsely High HbA1c Levels Measured By an Immunoassay. J Japan Diab Soc. 2016;59:463–8.
14.
Zurück zum Zitat Yamane Y, Tsumori M, Ishibashi M, Koga M. A case of variant hemoglobin (Hb Agenogi) with type 2 diabetes mellitus showed high HbA1c levels measured by immunoassay due to enhanced antigenicity. Diabetol Int. 2019;10:138–42.CrossRef Yamane Y, Tsumori M, Ishibashi M, Koga M. A case of variant hemoglobin (Hb Agenogi) with type 2 diabetes mellitus showed high HbA1c levels measured by immunoassay due to enhanced antigenicity. Diabetol Int. 2019;10:138–42.CrossRef
15.
Zurück zum Zitat Ohba Y, Miyaji T, Murakami M, et al. Hb Himeji or beta 140 (H18) Ala→Asp. A slightly unstable hemoglobin with increased beta N-terminal glycation. Hemoglobin. 1986; 10: 109–125. Ohba Y, Miyaji T, Murakami M, et al. Hb Himeji or beta 140 (H18) Ala→Asp. A slightly unstable hemoglobin with increased beta N-terminal glycation. Hemoglobin. 1986; 10: 109–125.
16.
Zurück zum Zitat Forget BG. Molecular genetics of human hemoglobin synthesis. Ann Intern Med. 1979;91:605–16.CrossRef Forget BG. Molecular genetics of human hemoglobin synthesis. Ann Intern Med. 1979;91:605–16.CrossRef
Metadaten
Titel
A case of α-chain variant hemoglobin (Hb Chad) with falsely high HbA1c levels measured by immunoassay
verfasst von
Kei Yoshino
Yushi Hirota
Wataru Ogawa
Kenji Sugawara
Akira Kawaguchi
Hiroshi Yoshino
Midori Ishibashi
Gen Yoshino
Masafumi Koga
Publikationsdatum
13.08.2021
Verlag
Springer Singapore
Erschienen in
Diabetology International / Ausgabe 1/2022
Print ISSN: 2190-1678
Elektronische ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-021-00529-y

Weitere Artikel der Ausgabe 1/2022

Diabetology International 1/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.